Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Total Liabilities (2023 - 2025)

Immunome's Total Liabilities history spans 3 years, with the latest figure at $48.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 17.32% year-over-year to $48.8 million; the TTM value through Dec 2025 reached $48.8 million, down 17.32%, while the annual FY2025 figure was $48.8 million, 17.32% down from the prior year.
  • Total Liabilities reached $48.8 million in Q4 2025 per IMNM's latest filing, up from $35.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $87.1 million in Q3 2023 to a low of $27.0 million in Q2 2025.
  • Average Total Liabilities over 3 years is $42.2 million, with a median of $35.5 million recorded in 2025.
  • The largest YoY upside for Total Liabilities was 106.14% in 2024 against a maximum downside of 51.78% in 2024.
  • A 3-year view of Total Liabilities shows it stood at $28.7 million in 2023, then soared by 106.14% to $59.1 million in 2024, then decreased by 17.32% to $48.8 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Total Liabilities are $48.8 million (Q4 2025), $35.5 million (Q3 2025), and $27.0 million (Q2 2025).